NAMSW NewAmsterdam Pharma Company N.V. - Warrant
NASDAQ · View on SEC EDGAR ↗ close Oct 1, 2026 10-K/10-Q Feb 18, 2026
$12.65
· of 52w range
· above low
· to high
$11.3752w low
$30.4552w high
Market Cap (MRQ)
$1.45B
P/E (TTM)
-7.4
EPS (TTM)
$-1.72
Revenue (TTM)
$23M
your badges
52W Range
$11–$30
Analyst Rating
·
Price Target
·
P/E
-7.4
ROE
-28.3%
Net Profit Margin
-905.7%
Your badge strip is empty — pin a metric anywhere on this page.
NAMSW Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$12.65
Market Cap (MRQ)
$1.45B
P/E (TTM)
-7.4
EPS (TTM)
$-1.72
Revenue (TTM)
$23M
ROE (TTM)
-28.3%
52W Range
$11–$30
NAMSW Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$23M2022-12-31 → 2025-12-31
EPS$-1.722020-12-31 → 2025-12-31
Free Cash Flow$-148M2022-12-31 → 2025-12-31
Net margin-905.7%2023-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | NAMSW | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -7.45Y avg ≈-5.3 | ≈-5.3 | · | · | |
| P/S (TTM) | 64.35Y avg ≈56.3 | ≈56.3 | · | · | |
| P/B (MRQ) | 2.15Y avg ≈2.3 | ≈2.3 | · | · | |
| Price / FCF (TTM) | -9.85Y avg ≈-9.8 | ≈-9.8 | · | · | |
| Price / Cash Flow (TTM) | -9.85Y avg ≈-9.8 | ≈-9.8 | · | · | |
| Price / Tangible Book | 2.15Y avg ≈2.3 | ≈2.3 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | NAMSW | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | -1002.9%5Y avg ≈-896.1% | ≈-896.1% | · | · | |
| EBITDA Margin (TTM) | -1001.9%5Y avg ≈-895.6% | ≈-895.6% | · | · | |
| Pretax Margin (TTM) | -905.7%5Y avg ≈-897.2% | ≈-897.2% | · | · | |
| Net Profit Margin (TTM) | -905.7%5Y avg ≈-897.2% | ≈-897.2% | · | · | |
| ROA (TTM) | -24.9%5Y avg ≈-33.5% | ≈-33.5% | · | · | |
| ROE (TTM) | -28.3%5Y avg ≈-42.4% | ≈-42.4% | · | · |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | NAMSW | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 7.95Y avg ≈8.9 | ≈8.9 | · | · | |
| Quick Ratio | 7.45Y avg ≈8.6 | ≈8.6 | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | NAMSW | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | -50.6%5Y avg ≈28.8% | ≈28.8% | · | · | |
| Revenue CAGR 3Y | -39.7% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | NAMSW | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.05Y avg ≈0.0 | ≈0.0 | · | · | |
| Revenue / Employee | ≈$225.0K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $23M | $46M | $14M | $103M | |
| R&D Expense | $142M | $151M | $159M | $87M | |
| SG&A Expense | $106M | $70M | $38M | $20M | |
| Operating Expenses | $248M | $222M | $197M | $106M | |
| Operating Income | $-226M | $-176M | $-183M | $-4M | |
| Interest Expense | · | · | · | $287.0K | |
| Interest Income | $28M | $17M | $11M | $11.0K | |
| Pretax Income | $-204M | $-242M | $-177M | $-23M | |
| Income Tax | · | $-1.0K | $27.0K | · | |
| Net Income | $-204M | $-242M | $-177M | $-23M | |
| EPS (Basic) | $-1.72 | $-2.56 | $-2.15 | $-1.19 | |
| EPS (Diluted) | $-1.72 | $-2.56 | $-2.15 | $-1.19 | |
| Shares (Basic) | 118,424,231 | 94,358,067 | 82,161,956 | 18,966,235 | |
| Shares (Diluted) | 118,424,231 | 94,358,067 | 82,161,956 | 18,966,235 | |
| EBITDA | $-225M | $-176M | $-183M | $-67M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Cash & Equivalents | $490M | $772M | $340M | $439M | |
| Short-term Investments | $146M | $62M | · | · | |
| Prepaid Expense | $38M | $24M | $6M | $10M | |
| Current Assets | $676M | $863M | $347M | $448M | |
| PP&E (Net) | $383.0K | $242.0K | $46.0K | $144.0K | |
| Intangibles | · | · | · | $83M | |
| Total Assets | $769M | $865M | $347M | $532M | |
| Accounts Payable | $9M | $5M | $17M | $19M | |
| Current Liabilities | $86M | $107M | $50M | $35M | |
| Capital Leases | $66.0K | $202.0K | · | $60.0K | |
| Total Liabilities | $86M | $107M | $59M | $48M | |
| Common Stock | $14M | $13M | $10M | $10M | |
| Retained Earnings | $-762M | $-559M | $-317M | $-140M | |
| AOCI | $5M | $4M | $4M | $4M | |
| Stockholders' Equity | $683M | $758M | $288M | $430M | |
| Liabilities + Equity | $769M | $865M | $347M | $478M | |
| Shares Outstanding | 114,399,326 | 108,064,340 | 82,469,768 | 81,559,780 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| D&A | $220.0K | $113.0K | $49.0K | $9.0K | |
| Stock-based Comp | $59M | $34M | $25M | $4M | |
| Other Non-cash | $-4M | $49M | $11M | $86M | |
| Operating Cash Flow | $-148M | $-159M | $-141M | $11M | |
| CapEx | $246.0K | $672.0K | $24.0K | $221.0K | |
| Investing Cash Flow | $-175M | $-63M | $-24.0K | $-221.0K | |
| Financing Cash Flow | $30M | $660M | $9M | $392M | |
| Free Cash Flow | $-148M | $-159M | $-141M | $8M |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating Margin | -1002.9% | -386.9% | -1298.6% | · | |
| Net Margin | -905.7% | -530.2% | -1255.8% | · | |
| Pretax Margin | -905.7% | -530.2% | -1255.6% | · | |
| EBITDA Margin | -1001.9% | -386.7% | -1298.2% | · | |
| ROA | -24.9% | -39.9% | -42.9% | -26.4% | |
| ROE | -27.9% | -42.5% | -57.1% | -42.1% | |
| ROIC | · | -23.3% | -63.4% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Current Ratio | 7.9 | 8.1 | 7.0 | 12.6 | |
| Quick Ratio | 7.4 | 7.8 | 6.8 | 12.4 | |
| Interest Coverage | · | · | · | -249.3 |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | 0.0 | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Book Value / Share | $5.97 | $7.01 | $3.50 | · | |
| Revenue / Share | $0.19 | $0.48 | $0.17 | · | |
| Cash Flow / Share | $-1.25 | $-1.68 | $-1.72 | · | |
| Cash / Share | $4.28 | $7.14 | $4.13 | · | |
| EPS (TTM) | $-1.72 | $-2.56 | $-2.15 | $-1.19 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue YoY | -50.6% | 223.4% | -86.3% | · | |
| Revenue CAGR 3Y | -39.7% | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue TTM | $23M | $46M | $14M | $103M | |
| Net Income TTM | $-204M | $-242M | $-177M | $-23M | |
| Market Cap | $2.63B | $1.54B | $258M | · | |
| P/E | -13.4 | -5.6 | -1.5 | -0.7 | |
| P/S | 116.9 | 33.8 | 18.3 | · | |
| P/B | 3.9 | 2.0 | 0.9 | · | |
| P / Tangible Book | 3.9 | 2.0 | 0.9 | · | |
| P / Cash Flow | -17.8 | -9.7 | -1.8 | · | |
| P / FCF | -17.8 | -9.7 | -1.8 | · | |
| Earnings Yield | -7.5% | -18.0% | -68.7% | -137.1% |
Income Statement
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $32.0K | $348.0K | $19M | $3M | $13M | $29M | $2M | $1M | $3M | $2M | $9M | |
| R&D Expense | $39M | $31M | $28M | $45M | $35M | $36M | $38M | $42M | $43M | $34M | $40M | |
| SG&A Expense | $27M | $25M | $27M | $27M | $21M | $18M | $16M | $14M | $9M | $10M | $8M | |
| Operating Expenses | $66M | $55M | $55M | $72M | $56M | $54M | $55M | $57M | $52M | $44M | $48M | |
| Operating Income | $-66M | $-55M | $-36M | $-69M | $-43M | $-25M | $-53M | $-55M | $-50M | $-42M | $-40M | |
| Interest Income | $6M | $7M | $7M | $7M | $4M | $4M | $5M | $3M | $3M | $5M | $943.0K | |
| Pretax Income | $-75M | $-72M | $-17M | $-40M | $-92M | $-17M | $-39M | $-94M | $-47M | $-38M | $-42M | |
| Income Tax | · | · | · | · | $0 | $-1.0K | · | · | · | · | · | |
| Net Income | $-75M | $-72M | $-17M | $-40M | $-92M | $-17M | $-39M | $-94M | $-47M | $-38M | $-42M | |
| EPS (Basic) | $-0.62 | $-0.61 | $-0.15 | $-0.34 | $-0.91 | $-0.18 | $-0.41 | $-1.06 | $-0.57 | $-0.47 | $-0.51 | |
| EPS (Diluted) | $-0.62 | $-0.61 | $-0.15 | $-0.34 | $-0.91 | $-0.18 | $-0.41 | $-1.06 | $-0.57 | $-0.47 | $-0.51 | |
| Shares (Basic) | · | 119,000,266 | 118,556,492 | 116,124,941 | · | 94,754,140 | 94,711,604 | 88,380,230 | 82,466,584 | 82,064,519 | 81,634,428 | |
| Shares (Diluted) | · | 119,000,266 | 118,556,492 | 116,124,941 | · | 94,754,140 | 94,711,604 | 88,380,230 | 82,466,584 | 82,064,519 | 81,634,428 | |
| EBITDA | · | $-55M | $-36M | $-69M | · | $-25M | $-53M | $-55M | · | · | · |
Balance Sheet
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $490M | $538M | $564M | $748M | $772M | $423M | $431M | $481M | · | · | · | |
| Short-term Investments | $146M | $165M | $175M | $60M | $62M | · | · | · | · | · | · | |
| Prepaid Expense | $38M | $28M | $31M | $9M | $24M | $15M | $15M | $7M | · | · | · | |
| Current Assets | $676M | $732M | $770M | $817M | $863M | $438M | $445M | $488M | · | · | · | |
| PP&E (Net) | $383.0K | $323.0K | $312.0K | $238.0K | $242.0K | $231.0K | $234.0K | $101.0K | · | · | · | |
| Total Assets | $769M | $786M | $815M | $818M | $865M | $439M | $447M | $488M | · | · | · | |
| Accounts Payable | $9M | $4M | $6M | $6M | $5M | $7M | $5M | $9M | · | · | · | |
| Current Liabilities | $86M | $58M | $37M | $41M | $107M | $41M | $45M | $60M | · | · | · | |
| Capital Leases | $66.0K | $85.0K | $103.0K | $137.0K | $202.0K | $266.0K | $328.0K | · | · | · | · | |
| Total Liabilities | $86M | $58M | $37M | $41M | $107M | $60M | $59M | $77M | · | · | · | |
| Common Stock | $14M | $14M | $14M | $14M | $13M | $11M | $11M | $11M | · | · | · | |
| Retained Earnings | $-762M | $-687M | $-615M | $-598M | $-559M | $-466M | $-450M | $-411M | · | · | · | |
| AOCI | $5M | $5M | $4M | $4M | $4M | $4M | $4M | $4M | · | · | · | |
| Stockholders' Equity | $683M | $728M | $778M | $777M | $758M | $379M | $387M | $412M | · | · | · | |
| Liabilities + Equity | $769M | $786M | $815M | $818M | $865M | $439M | $447M | $488M | · | · | · | |
| Shares Outstanding | 114,399,326 | 113,172,684 | 112,509,914 | 112,169,291 | 108,064,340 | 92,165,605 | 90,015,357 | 89,720,836 | · | · | · |
Cash Flow
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $59.0K | $64.0K | $45.0K | $52.0K | $51.0K | $28.0K | $19.0K | $15.0K | $14.0K | $13.0K | $9.0K | |
| Stock-based Comp | $14M | $15M | $15M | $15M | $9M | $8M | $8M | $8M | $5M | $6M | $8M | |
| Other Non-cash | · | · | · | $-12M | · | · | · | $31M | · | · | · | |
| Operating Cash Flow | $-41M | $-33M | $-38M | $-36M | $-37M | $-13M | $-54M | $-55M | $-47M | $-29M | $-32M | |
| CapEx | $100.0K | $42.0K | $88.0K | $16.0K | $3.0K | $75.0K | $209.0K | $385.0K | $9.0K | $5.0K | $7.0K | |
| Investing Cash Flow | $-21M | $3M | $-159M | $3M | $-62M | $-75.0K | $-209.0K | $-385.0K | $-9.0K | $-5.0K | $-7.0K | |
| Financing Cash Flow | $14M | $6M | $3M | $7M | $457M | $58.0K | $5M | $198M | $186.0K | $6M | $2M | |
| Free Cash Flow | · | · | · | $-36M | · | · | · | $-55M | · | · | · |
Profitability
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | -15845.7% | -186.1% | -2314.5% | · | -85.9% | -2306.9% | -3960.2% | · | · | · | |
| Net Margin | · | -20691.1% | -90.7% | -1327.3% | · | -57.2% | -1711.6% | -6692.9% | · | · | · | |
| Pretax Margin | · | -20691.1% | -90.7% | -1327.3% | · | -57.2% | -1711.6% | -6692.9% | · | · | · | |
| EBITDA Margin | · | -15845.7% | -186.1% | -2312.7% | · | -85.9% | -2306.9% | -3959.1% | · | · | · | |
| ROA | · | -11.8% | -2.8% | -6.0% | · | -7.6% | -17.5% | -38.4% | · | · | · | |
| ROE | · | -13.0% | -3.0% | -6.7% | · | -8.8% | -20.1% | -45.5% | · | · | · | |
| ROIC | · | · | · | · | · | -6.6% | · | · | · | · | · |
Liquidity & Solvency
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 12.6 | 21.1 | 20.0 | · | 10.6 | 9.8 | 8.2 | · | · | · | |
| Quick Ratio | · | 12.1 | 20.2 | 19.8 | · | 10.2 | 9.5 | 8.1 | · | · | · |
Efficiency
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.0 | 0.0 | 0.0 | · | 0.1 | 0.0 | 0.0 | · | · | · |
Per Share
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | · | $6.43 | $6.92 | $6.93 | · | $4.11 | $4.30 | $4.59 | · | · | · | |
| Revenue / Share | · | $0.00 | $0.16 | $0.03 | · | $0.31 | $0.02 | $0.02 | · | · | · | |
| Cash Flow / Share | · | · | · | $-0.31 | · | · | · | $-0.62 | · | · | · | |
| Cash / Share | · | $4.76 | $5.01 | $6.67 | · | $4.59 | $4.78 | $5.36 | · | · | · | |
| EPS (TTM) | · | $-2.01 | $-1.58 | $-1.84 | · | $-2.25 | $-2.64 | $-2.70 | · | · | · |
Valuation (TTM)
| Metric | Trend | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | $35M | $64M | $47M | · | $34M | $7M | $7M | · | · | · | |
| Net Income TTM | · | $-221M | $-166M | $-187M | · | $-199M | $-229M | $-229M | · | · | · | |
| Market Cap | · | $1.94B | $900M | $1.01B | · | $645M | $785M | $991M | · | · | · | |
| P/E | · | -8.5 | -5.1 | -4.9 | · | -3.1 | -3.3 | -4.1 | · | · | · | |
| P/S | · | 54.9 | 14.1 | 21.4 | · | 19.2 | 105.7 | 144.3 | · | · | · | |
| P/B | · | 2.7 | 1.2 | 1.3 | · | 1.7 | 2.0 | 2.4 | · | · | · | |
| P / Tangible Book | · | 2.7 | 1.2 | 1.3 | · | 1.7 | 2.0 | 2.4 | · | · | · | |
| P / Cash Flow | · | · | · | -27.7 | · | · | · | -18.1 | · | · | · | |
| Earnings Yield | · | -11.8% | -19.8% | -20.5% | · | -32.1% | -30.3% | -24.5% | · | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $23M | $46M | $14M | $103M | · |
| Operating Margin % | -1002.9% | -386.9% | -1298.6% | · | · |
| Net Income | $-204M | $-242M | $-177M | $-23M | $-29M |
| Diluted EPS | $-1.72 | $-2.56 | $-2.15 | $-1.19 | $-1.21 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 7.9 | 8.1 | 7.0 | 12.6 | · |
| Quick Ratio | 7.4 | 7.8 | 6.8 | 12.4 | · |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $-148M | $-159M | $-141M | $8M | · |
Institutional owners (13F) 11 filers · $29.6M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
11
Value held
$29.6M
New positions
0
Exited positions
0
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 0 (-1 vs prior Q) | 0 (0 vs prior Q) | 2 (+2 vs prior Q) | 0 (-1 vs prior Q) | +13K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | $10,692,116 | 500,333 | 36.15% | Shares |
| RA CAPITAL MANAGEMENT, L.P. | $7,123,326 | 333,333 | 24.09% | Shares |
| Affinity Asset Advisors, LLC | $5,343,450 | 245,000 | 18.07% | Shares |
| Bain Capital Life Sciences Investors, LLC | $2,136,979 | 99,999 | 7.23% | Shares |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $1,982,858 | 92,787 | 6.70% | Shares |
| MILLENNIUM MANAGEMENT LLC | $1,602,750 | 75,000 | 5.42% | Call option |
| ARISTEIA CAPITAL, L.L.C. | $343,377 | 15,708 | 1.16% | Shares |
| WOLVERINE ASSET MANAGEMENT LLC | $318,947 | 14,925 | 1.08% | Shares |
| CIBC Private Wealth Group LLC | $22,388 | 1,250 | 0.08% | Shares |
| UBS Group AG | $8,523 | 443 | 0.03% | Shares |
| Vestcor Inc | $143 | 6,666 | 0.00% | Shares |
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| FHMLS X, L.L.C., FHMLS X, L.P., FHMLS XI, L.L.C., FHMLS XI, L.P., FHMLS XII, L.L.C., FHMLS XII, L.P., FHMLSP, L.L.C., FHMLSP, L.P., Frazier Life Sciences Public Fund, L.P., Frazier Life Sciences X, L.P., Frazier Life Sciences XI, L.P., Frazier Life Sciences XII, L.P., Frazier Lifesciences Sponsor LLC, James N. Topper, Patrick J. Heron | Sept. 22, 2026 | 8.70% | Amendment | · | SEC |
| BCLS Fund III Investments, LP, Bain Capital Life Sciences Opportunities III, LP, Bain Capital Life Sciences Fund II, L.P., BCLS II Investco, LP, BCLS II Equity Opportunities, LP, BCIP Life Sciences Associates, LP | May 14, 2026 | 1.76% | Amendment | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 5 insiders · 4 officers · 3 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Michael H. Davidson | Chief Executive Officer | Sept. 14, 2026 P | 792,923 | 1 | 0 | $226,500 |
| Johannes Jacob Pieter Kastelein | Chief Scientific Officer | Sept. 30, 2026 M | 69,302 | 0 | 2 | $-4,621,407 |
| Robert William Gunning | Vice President, Controller | Sept. 1, 2026 A | 3,200 | 0 | 0 | $0 |
| Louise Frederika Kooij | Chief Accounting Officer | July 20, 2026 M | 24,353 | 0 | 5 | $-4,393,815 |
| John W Smither | Director | Sept. 4, 2026 S | 8,760 | 0 | 1 | $-40,512 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-K filed Feb 18, 2026